Revolution Medicines’ pancreatic cancer drug Rasonque drew fresh scrutiny after FDA review documents and new dataset readouts suggested narrower performance than investors had assumed. In trading, the stock reaction underscored how subgroup effects and mutation-dependent response can rapidly reframe expectations. Separately, Ultragenyx received a cash infusion, adding financial runway for ongoing development plans, while TCGX launched a China-focused fund aimed at funding pipeline growth. Together, the items highlight a two-track market dynamic: regulatory messaging can move valuations even before definitive endpoints land, while capital formation continues to target late-stage and geography-expansion opportunities.